Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
October 30, 2024
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
There are currently no regenerative treatments for any lung disease, including IPF, which is a deadly condition characterized by extensive tissue damage and permanent lung scarring, says Chan Beals, MD, chief medical officer of Calibr-Skaggs. Based on our encouraging preclinical data, CMR316 has the potential to halt or even reverse IPF, in addition to other severe lung conditions such as chronic obstructive pulmonary disease. This clinical milestone achieved through the collaborative bench to bedside' model of Scripps Research and Calibr-Skaggs scientists brings us closer to delivering a first-in-class medicine that could transform the lives of many people affected by debilitating lung diseases.
IPF is a severe, chronic, and progressive disease with no known cause and no cure. It affects roughly 100,000 people in the United States, drastically reducing their quality of life. With ever-increasing fibrosis in the lung over time, IPF progresses from mild shortness of breath and dry cough during activity to an inability to breathe even at rest. Difficulty breathing can lead to pulmonary hypertension and respiratory failure, preventing the brain and other organs from receiving adequate oxygen. There is no cure for IPF, aside from a lung transplant which is rarely an option, and tragically, patient survival after diagnosis is a mere 2 5 years. Available treatments, such as anti-fibrotics, can only slow disease progression and manage symptoms, highlighting the critical need for innovative new therapies. With an understanding that the lung's natural yet limited capacity to regenerate and repair is impaired in IPF, a new therapeutic strategy has emerged.
CMR316 is a first-in-class drug designed to precisely stimulate lung stem cells to regenerate lung tissue. Specifically, CMR316 targets type 2 alveolar epithelial cells (AEC2s) the stem cells in the lower airway of the lungs that are reduced in patients with IPF. Stimulating AEC2 stem cells causes them to differentiate into type 1 AEC (AEC1) cells that are crucial for gas exchange and maintaining lung stability and function. Thus, stimulating AEC2 stem cells with CMR316 has potential to repair damage caused by many lung conditions, including IPF. Furthermore, CMR316's regenerative mechanism is distinct yet complementary to that of approved anti-fibrotics, which could allow them to be combined for even greater effect.
CMR316 was discovered and developed through a partnership between Scripps Research and Calibr-Skaggs scientists, led by President and CEO Peter Schultz, PhD, and Associate Professor of Chemistry Michael Bollong, PhD, who is the Early Endowed Roon Chair for Cardiovascular Research. In April 2024, they published a study in the Proceedings of the National Academy of Sciences, which provided proof of concept for CMR316's ability to stimulate AEC2s to regenerate lung tissue in IPF and several other lung disease models.
From this foundational bench' research, the Calibr-Skaggs drug development team, led by Vice President of Pharmacology Sean Joseph, PhD, performed critical preclinical safety studies and received regulatory approval to reach the bedside' for testing CMR316 in humans.
Through careful testing of CMR316 over the last few years a huge team effort we are cautiously optimistic that the benefits and exceptional safety profile we observed preclinically will translate to patients with lung diseases, including those with IPF, says Joseph.
CMR316 is being tested at Fraunhofer ITEM in Hanover, Germany in an extensive phase 1 study in healthy volunteers (Parts 1 and 2) and patients with IPF (Part 3). The study title is A Phase 1/1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Nebulized CMR316 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis (EU trial number: 2023-510456-23-00). The main objective of the trial is to assess the safety and tolerability of single (Part 1) and multiple inhaled doses of CMR316 in healthy volunteers (Part 2) and patients with IPF (Part 3).
This work was supported by funding from Calibr-Skaggs, with additional support from the Bachrach Family Foundation.
Calibr-Skaggs Schultz, Peter Bollong, Michael
Most recent headlines
16/12/2025
Hawkins has landed on Spotify, just in time for Stranger Things Season 5, Volume...
16/12/2025
Wherever you are, your favorite music and audio content should go seamlessly with you. That's why Spotify has partnered with NAVER Corp, Korea's leading...
16/12/2025
2025 Wrapped arrived bigger and bolder than ever. This year's experience is designed to be ultra personal and shareable, with new features like Wrapped Part...
16/12/2025
Three 12-kilowatt Advanced Electric Propulsion System thrusters, supplied by L3Harris Technologies, form the core of Gateway's propulsion system. Pictured i...
16/12/2025
The challenge facing America's defense industrial base is not just about speed - its about rebuilding the foundation that makes speed possible. Our nations ...
16/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
16/12/2025
SEVILLE, Spain Canal Sur, the public broadcasting service for Andalusia, Spain, has completed a total technology refresh based on Pebble's resilient, softwa...
16/12/2025
NEW YORK Teleprompting hardware provider Telescript International has acquired all software code and intellectual property previously owned by Telescript West. ...
16/12/2025
As cable operators face increased competition from 5G fixed wireless access providers, a new report from Ookla Research finds that T-Mobile is the FWA speed lea...
16/12/2025
Apple has announced a major upgrade to the Apple TV app for device owners outside the Apple ecosystem with news that the Apple TV app for Android now supports G...
16/12/2025
Space42 grows Direct-to-Device partner ecosystem through a Memorandum of Underst...
16/12/2025
16 Dec 2025
VEON Announces Release Date for Full Year and Fourth Quarter 2025 R...
16/12/2025
16 Dec 2025
VEON's Kyivstar Invests in Renewable Energy in Ukraine with Acq...
16/12/2025
Back to All News
Emma Appleton, Fares Fares, Frida Gustavsson and Jakob Oftebro...
16/12/2025
Back to All News
Docu-reality My Korean Boyfriend Gets a Trailer and Premiere D...
16/12/2025
Harmonic's XOS Advanced Media Processor Improves Streaming Video Quality and Boosts Viewer Engagement SAN JOSE, Calif. - Dec. 16, 2025 - Harmonic (NASDAQ: ...
16/12/2025
RT Sport Awards 2025 live on RT One and RT Player at 8:05pm on Saturday 20 December.
On Saturday 20 December live on RT One and RT Player at the earlier t...
16/12/2025
Singer -songwriter Brian Kennedy has been announced as the final celebrity dance...
15/12/2025
Harlem Globetrotters Celebrate 100th Anniversary With New Brand Campaign From Th...
15/12/2025
Top L-R: La Tierra Del Valor (The Home of the Brave), Mangittatuarjuk (The Gnawe...
15/12/2025
L3Harris will leverage 15 years of experience supporting the E-4B Nightwatch and...
15/12/2025
CONWAY, Ark. In a notable example of how the loss of federal funding is forcing public stations to make massive cuts and operational changes, the statewide pub...
15/12/2025
BOULDER, Colo. Public Media Venture Group (PMVG), Venture Technologies Group (VTG), and WQED have completed a multipart agreement that they say will significant...
15/12/2025
Cape Town, November 13, 2025 - SES and International artist and humanitarian, Fo...
15/12/2025
Luxembourg, December 15, 2025 - SES, a leading space solutions company, and Abra Group launched fast and reliable multi-orbit inflight connectivity service on t...
15/12/2025
How Rivian s Design Puts Drivers First-And Why That Matters Published on Dec 15, 2025 Categories: Business Solutions
LinkedIn Corporate Communications
Sha...
15/12/2025
Space42 and Cobham Satcom completed the full range of advanced terminals for the...
15/12/2025
15 Dec 2025
VEON's Beeline Kazakhstan Delivers First Starlink Direct to Cel...
15/12/2025
Andrew Mountbatten-Windsor finds himself the topic of year's cracker jokes
Oasis, David Harbour, Celebrity Traitors and Angela Rayner all feature in this y...
15/12/2025
Comscore Expands Cross-Platform Campaign Measurement to Include Audio and Social New capabilities strengthen cross-platform campaign reporting suite; CCR rebran...
15/12/2025
NVIDIA today announced it has acquired SchedMD - the leading developer of Slurm, an open-source workload management system for high-performance computing (HPC) ...
15/12/2025
RT .ie has reached one billion page views this year and is on track to finish 2025 2% ahead of last year. Average time spent on the site is up 3% on 2024, with ...
15/12/2025
Modern workflows showcase the endless possibilities of generative and agentic AI on PCs.
Of many, some examples include tuning a chatbot to handle product-supp...
13/12/2025
Powering Client Growth: Horizon Deepens Nielsen Partnership, Enabling More Effic...
13/12/2025
In a move that will help it offer more flexible and less costly programming options, YouTube TV has announced that it will be launching YouTube TV Plans with mo...
13/12/2025
SINGAPORE Magna Systems has designed, built and completed what is believed to be the first full UHD and IP-based OB truck in Southeast Asia for a Singapore medi...
12/12/2025
SVG Summit 2025 Preview: Everything You Need to Know for Next Week's Big Sho...
12/12/2025
Hailey Gates at the Atropia premiere (photo by George Pimentel / Shutterstock for Sundance Film Festival)...
12/12/2025
Last month, Spotify announced a new collaboration with the ATP Tour, the global governing body of men's professional tennis, aimed at bringing the next gene...
12/12/2025
CONWAY, Ark. In a notable example of how the elimination of Federal federal funding is forcing public stations to make massive cuts and changes in the way they...
12/12/2025
Wisycom and DPA Microphones announce the appointment of Ren Moerch as Group Product Director, Wireless, a strategic leadership role that will guide the combine...
12/12/2025
SMPTE , the home of media professionals, technologists, and engineers, in conjuncture with the European Broadcasting Union (EBU) and the Entertainment Technolog...
12/12/2025
Keepit, the vendor-independent, cloud-native data protection provider, today announced a strategic go-to-market relationship in Poland with Ingram Micro, a lead...
12/12/2025
Atomos announced the immediate availability of a new firmware update for its Ninja TX GO and Ninja TX monitor-recorders, unlocking Open Gate 48P RAW recording w...
12/12/2025
Professional Wireless Systems (PWS) once again played a critical role in delivering flawless wireless coordination and support at the 2025 Latin Grammy Awards a...
12/12/2025
The Alliance for IP Media Solutions (AIMS), together with the Video Services Forum (VSF), the Advanced Media Workflow Association (AMWA) and the European Broadc...
12/12/2025
DHD audio will demonstrate the latest additions to its range of digital audio production solutions on Booth 321 in Hall B6 at Hamburg Open 2026. The show will b...
12/12/2025
Chaos today announces the release of V-Ray for Blender, update 2, bringing its award-winning rendering technology to even more Blender users by adding support f...
12/12/2025
Lighting specialist UltraLEDs has launched Precision LED Tape, a high-CRI lighting solution designed specifically for professional film, TV, and studio use.
P...
Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
